KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of thoracic disease"
DOI: 10.21037/jtd.2019.07.80
Abstract: Immunotherapy with monoclonal antibodies against programmed death-1 (PD-1) or its ligand (PD-L1) were approved for previously treated advanced non-small cell lung cancer (NSCLC) based on the results from four randomized trials showing improved survival compared… read more here.
Keywords: role; pembrolizumab; previously treated; keynote 042 ... See more keywords